Platelet α2-adrenoceptor alterations in patients with essential hypertension

British Journal of Clinical Pharmacology

Volumn 47, Issue 2, 1999, Pages 167-172

  Varani, Katia ^a   Gessi, Stefania ^a   Caiazza, Alberto ^b   Rastelli, Gianni ^b   Portaluppi, Francesco ^a   Borea, Pier Andrea ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b Fidenza Hospital   (Italy)

Author keywords

3H UK 14304 binding; cAMP; G proteins; Human platelets

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRIMONIDINE; CYCLIC AMP; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; ADRENALIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; FORSKOLIN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); QUINOXALINE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HYPERTENSION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; THERMODYNAMICS; THROMBOCYTE;

ADRENERGIC ALPHA-ANTAGONISTS; BLOOD PLATELETS; CYCLIC AMP; EPINEPHRINE; FEMALE; FORSKOLIN; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROTEIN BINDING; QUINOXALINES; RECEPTORS, ADRENERGIC, ALPHA-2; THERMODYNAMICS;

EID: 0032587435     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00866.x     Document Type: Article

References (29)

1. Gavras H, Handy D, Gavras I. Alpha-adrenergic receptors in hypertension. In Hypertension: Pathophysiology, Diagnosis, and Management. Eds J.H. Laragh, B.M. Brenner. New York: Raven Press, 1995, 853-861.
2. Brodde OE, Daul AE, O'Hara N, Khalifa AM. Properties of α- and β-adrenoceptors in circulating blood cells of patients with essential hypertension. J Cardiovasc Pharmacol 7 (Suppl 6); 1985: S162-S167.
3. Brodde OE, Beckering JJ, Michel MC. Human heart β-adrenoceptors: a fair comparison with lymphocyte β-adrenoceptors? Trends Pharmacol Sci 1987; 8: 403-407.
4. Michel MC, Brodde OE, Insel PA. Peripheral adrenergic receptors in hypertension. Hypertension 1990; 16: 107-120.
5. Blankesteijn, WM, Graafsma SJ, van Tits LJH, Hectors MPC, Thien T. Adrenoceptors on blood cells in patients with primary hypertension: correlation with blood pressure and related variables. J Hypertens 1993; 11: 995-1002.
6. Taylor P, Insel PA. Molecular basis of pharmacologic selectivity. In: Principles of Drug Action-The Basis of Pharmacology. edited by Pratt WB, Taylor P, New York: Churchill Livingstone, 1990; 1-102.
7. 2-adrenoceptor subtypes. Br J Pharmacol 1993; 109: 371-378, 1993
8. 3H]-UK-14304: regulation by Gpp(NH)p and cations. Naunyn Schmiedeberg's Arch Pharmacol 1987; 336: 48-59.
9. The fifth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNCV). Arch Intern Med 1993; 153: 154-183.
10. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye-binding. Anal Biochem 1976; 72: 248.
11. Munson PJ, Rodbard D. Ligand: a versatile computerized approach for the characterization of ligand binding systems. Anal Biochem 1980; 107: 220-239.
12. 35S]thio) triphosphate binding. Mol Pharmacol 1993; 44: 115-123.
13. Korth R, Nunez D, Bidault J, Benveniste J. Comparison of three paf-acether receptor antagonist ginkgolides. Eur J Pharmacol 1988; 152: 101-110.
14. Nordstedt C, Fredholm MM. A modification of a protein-binding method for rapid quantification of cAMP in cell culture supernatants and body fluids. Anal Biochem 1990; 189: 231-234.
15. 3H]-UK 14304. J Neurochem 1989; 52: 1210-1217.
16. 2-adrenoceptor. Nature 1995; 374: 272-276.
17. 2-adrenoceptors in major affective disorder. Arch Gen Psychiatry 1986; 43: 51-57.
18. Kenakin T. Stimulus-response mechanisms: Pharmacologic Analysis of Drug-Receptor Interaction. New York: Raven Press, 1993, 39-68.
19. Marcil J, Schiffrin EL, Anand-Srivastava MB. Aberrant adenylyl cyclase/cAMP signal transduction and G protein levels in platelets from hypertensive patients improve with antihypertensive drug therapy. Hypertension 1996; 28: 83-90.
20. Esler M, Jennings G, Biviano B, Lambert G, Hasking G. Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol 1986; 8(suppl 5): S39-S43.
21. Esler M, Jenings G, Komer P, et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 1988; 11: 3-20.
22. Guzzetti S, Piccaluga E, Csati R, et al. Sympathetic predominance in essential hypertension: a study employing spectral analysis of heart rate variability. J Hypertens 1988; 6: 711-717.
23. Yamada Y, Miyajima E, Tochikubo O, Ishii M. Age-related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension 1989; 13: 870-877.
24. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension 1989; 14: 177-183.
25. Goldstein DS. Plasma catecholamines and essential hypertension. An analytical review. Hypertension 1983; 5: 86-99.
26. Yoshiro T, Miura Y, Kimura S, et al. Functional relationships between platelet alpha2-adrenoceptors and sympathetic nerve activity in clinical hypertensive states. J Hypertens 1990; 8: 1097-1104.
27. Nicholas AP, Pieribone V, Hokfelt T. Distributions of mRNAs for alpha-2 adrenergic receptor subtypes in rat brain: an in situ hybridization study. J Comp Neurol 1993; 328: 575-594.
28. Link RE, Desai K, Hein L, et al. Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c. Sciences 1996; 273: 803-805.
29. MacMillan LB, Hein L, Smith MS, Piascik MT, Limbird LE. Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science 1996; 273: 801-803.